1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 8, 1997 (Date of earliest event reported) Cephalon, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19119 23-2484489 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) ID No.) 145 Brandywine Parkway West Chester, Pennsylvania 19380 (Address of principal executive offices) (Zip Code) (610) 344-0200 (Registrant's telephone number, including area code) Not Applicable (Former name, former address and former fiscal year, if changed since last report) 2 ITEM 5. OTHER EVENTS. On May 8, 1997, Cephalon, Inc. (the "Registrant") announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration had found, by a vote of 6 to 3, that there was not substantial evidence that MYOTROPHIN(R) (rhIGF-1 or mecasermin) Injection is effective in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The Registrant hereby incorporates by reference the Press Release, which is attached hereto as Exhibit 99.1 and made a part hereof, into this Item 5. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (a) Financial Statements of Business Acquired: None (b) Pro Forma Financial Information: None (c) Exhibits: Reference is made to the Exhibit Index annexed hereto and made a part hereof. 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CEPHALON, INC. Date: May 8, 1997 By: /s/ Bruce A. Peacock --------------------- Bruce A. Peacock Executive Vice President and Chief Operating Officer 4 EXHIBIT INDEX EXHIBIT PAGE - ------- ---- 99.1 Press Release dated May 8, 1997